Colgate-Palmolive (NYSE:CL) Stock Gets Price Target Reduction from JPMorgan Chase & Co.

Posted by Brian Himes on Nov 2nd, 2026

Colgate-Palmolive (NYSE:CL – Get Free Report) had its price objective lowered by analysts at JPMorgan Chase & Co. from $104.00 to $102.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 5.72% from the stock’s previous close.

Several other equities analysts have also commented on the company. Bank of America increased their price objective on Colgate-Palmolive from $100.00 to $105.00 and gave the company a “buy” rating in a research report on Monday. BNP Paribas Exane decreased their price objective on Colgate-Palmolive from $101.00 to $97.00 and set an “outperform” rating on the stock in a report on Monday, September 28th. UBS Group restated a “buy” rating and issued a $112.00 target price on shares of Colgate-Palmolive in a research report on Monday. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $101.00 target price (up from $99.00) on shares of Colgate-Palmolive in a research note on Monday, August 3rd. Finally, Morgan Stanley reiterated an “overweight” rating and set a $104.00 price target (up from $100.00) on shares of Colgate-Palmolive in a research report on Monday, August 3rd. Thirteen analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $99.39.

Get Our Latest Analysis on CL

Colgate-Palmolive Price Performance

NYSE:CL traded up $1.19 during midday trading on Monday, hitting $96.48. The company had a trading volume of 590,249 shares, compared to its average volume of 5,621,402. Colgate-Palmolive has a 52-week low of $74.54 and a 52-week high of $99.33. The stock’s fifty day moving average price is $89.54 and its 200-day moving average price is $89.65. The company has a market capitalization of $76.91 billion, a PE ratio of 37.81, a P/E/G ratio of 4.59 and a beta of 0.31. The company has a quick ratio of 0.30, a current ratio of 0.46 and a debt-to-equity ratio of 13.82.

Colgate-Palmolive (NYSE:CL – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. Colgate-Palmolive had a return on equity of 607.88% and a net margin of 9.65%. The business had revenue of $5.37 billion for the quarter, compared to the consensus estimate of $5.34 billion. During the same quarter last year, the business posted $0.91 earnings per share. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. As a group, research analysts expect that Colgate-Palmolive will post 3.89 earnings per share for the current year.

Insider Buying and Selling at Colgate-Palmolive

In other news, COO Panagiotis Tsourapas sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $92.05, for a total value of $920,500.00. Following the transaction, the chief operating officer owned 64,901 shares in the company, valued at approximately $5,974,137.05. This trade represents a 13.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John T. Cahill sold 4,170 shares of Colgate-Palmolive stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $93.37, for a total transaction of $389,352.90. Following the completion of the transaction, the director directly owned 28,373 shares in the company, valued at approximately $2,649,187.01. The trade was a 12.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 175,191 shares of company stock worth $16,110,903. 0.43% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Colgate-Palmolive

Several institutional investors have recently added to or reduced their stakes in the company. State Street Corp raised its stake in shares of Colgate-Palmolive by 97.4% during the second quarter. State Street Corp now owns 94,195,992 shares of the company’s stock valued at $8,635,889,000 after acquiring an additional 46,476,510 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Colgate-Palmolive by 172.5% in the 1st quarter. Bank of New York Mellon Corp now owns 12,521,545 shares of the company’s stock worth $1,067,211,000 after purchasing an additional 7,927,238 shares during the period. Bank of America Corp DE bought a new stake in shares of Colgate-Palmolive during the 2nd quarter valued at about $567,483,000. Envestnet Asset Management Inc. boosted its stake in shares of Colgate-Palmolive by 266.5% during the 2nd quarter. Envestnet Asset Management Inc. now owns 4,146,337 shares of the company’s stock valued at $380,136,000 after purchasing an additional 3,014,860 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in Colgate-Palmolive by 151.4% in the third quarter. Assenagon Asset Management S.A. now owns 4,276,774 shares of the company’s stock worth $364,894,000 after buying an additional 2,575,530 shares during the period. Hedge funds and other institutional investors own 80.41% of the company’s stock.

More Colgate-Palmolive News

Here are the key news stories impacting Colgate-Palmolive this week:

Positive Sentiment: Colgate-Palmolive exceeded third-quarter expectations, reporting adjusted EPS of $0.97 versus the $0.93 consensus and revenue of $5.37 billion, up 4.6% year over year. Management also raised its margin and EPS outlook while narrowing its 2026 sales-growth range. Colgate-Palmolive sales rise 4.6% and it lifts margin and EPS outlook
Positive Sentiment: Royal Bank of Canada raised its price target from $104 to $105 and maintained an “outperform” rating, implying roughly 8.9% potential upside from the referenced share price. Royal Bank of Canada recommendations
Positive Sentiment: Analysts broadly lifted their forecasts after the earnings beat and higher EPS guidance, reinforcing the view that pricing, productivity initiatives and resilient household-products demand are supporting results. Colgate-Palmolive analysts boost forecasts after upbeat Q3 earnings
Positive Sentiment: Through the third quarter, free cash flow increased 7% and the company returned $2.2 billion to shareholders year to date, supporting the investment case for cash generation and capital returns. Colgate-Palmolive key takeaways for long-term investors

Colgate-Palmolive Company Profile

(Get Free Report)

Colgate-Palmolive Company (NYSE: CL) is a global consumer products company focused on oral care, personal care, home care and pet nutrition. Its portfolio includes toothpaste, toothbrushes, mouthwash, liquid hand soap, body wash, deodorants, household cleaning products and pet food and treats.

The company markets well-known brands such as Colgate, Palmolive, elmex, meridol, Softsoap, Irish Spring, Ajax, Protex and Hill’s Science Diet. Colgate-Palmolive also provides veterinary and nutritional products through Hill’s Pet Nutrition, which serves pet owners and animal health professionals.

Founded in 1806 by William Colgate, the company developed from a soap and candle business into a diversified consumer goods manufacturer.